GlassScriptPhysician profile
Kenesha P Colson
NPI 1912333840
$1,547.76
in general payments reported to CMS, 2019-2025
24 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $80.56 · 2023: $455 · 2024: $454 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.78 |
| Education | $199.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $215.14 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $196.96 | 2022-2025 | |
| Daiichi Sankyo INC. | $156.24 | 2022-2024 | Injectafer |
| Hologic Sales and Service, LLC | $126.44 | 2021-2025 | Aptima |
| Intuitive Surgical, INC. | $100.00 | 2024 | |
| Abbvie INC. | $82.08 | 2021-2023 | |
| Aspira Women'S Health INC | $78.40 | 2021-2024 | Ova1 |
| Shield Therapeutics INC | $73.30 | 2025 | |
| Biogen, INC. | $51.74 | 2024 | Zurzuvae |
| Allergan, INC. | $50.33 | 2021 | |
| Ascend Therapeutics US, LLC | $46.50 | 2023 | |
| Dynavax Technologies Corporation | $43.59 | 2021 | |
| Supernus Pharmaceuticals, INC. | $41.58 | 2021 | |
| Evofem Biosciences, INC. | $41.11 | 2021-2024 | |
| Myriad Women'S Health, INC. | $34.25 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $33.05 | 2023 | Myfembree |
| Biohaven Pharmaceuticals, INC. | $27.05 | 2021 | |
| Upsher-Smith Laboratories LLC | $26.22 | 2021 | |
| Lundbeck LLC | $25.45 | 2021 | |
| Organon LLC | $25.08 | 2023 | Nexplanon |
| Becton, Dickinson and Company | $21.42 | 2023 | Bd Onclarity |
| Minerva Surgical, INC | $18.76 | 2024 | |
| Millicent US INC | $18.52 | 2025 | Intrarosa, Femring |
| Pfizer INC. | $14.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenesha Colson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.